CONTACT
+91 80 2808 2808
ContactUs.BBL@biocon.com

IMMUNOLOGY

Biocon Biologics has one of the deepest portfolios of biosimilars in the industry, including several molecules in immunology. Two molecules, in-licensed from partners, have been commercialized.

Adalimumab*

Approved: Registered in the U.S., Europe, Canada, Japan, select markets across MoW (Most of the World).

Launched: Commercialized in Europe, Canada

Preclinical

Clinical

Filed

Approved

Launched

*Product in-licensed from Fujifilm Kyowa Kirin Biologics

Etanercept

Approved: Registered in Europe

Launched: Commercialized in Europe

Preclinical

Clinical

Filed

Approved

Launched

*Product in-licensed from Lupin

Ustekinumab

Preclinical

Clinical

Filed

Approved

Launched

Share